keyword
MENU ▼
Read by QxMD icon Read
search

Graves' orbitopathy

keyword
https://www.readbyqxmd.com/read/27902601/time-course-of-graves-orbitopathy-after-total-thyroidectomy-and-radioiodine-therapy-for-thyroid-cancer
#1
Camille Louvet, Annamaria De Bellis, Bruno Pereira, Claire Bournaud, Antony Kelly, Salwan Maqdasy, Beatrice Roche, Francoise Desbiez, Francoise Borson-Chazot, Igor Tauveron, Marie Batisse-Lignier
The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specifically investigated.The aim of this study is to assess the influence of RAI treatment administered for differentiated thyroid cancer on the course of a pre-existing GO...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27895458/clinical-and-imaging-evaluation-of-the-response-to-intravenous-steroids-in-patients-with-graves-orbitopathy-and-analysis-on-who-requires-additional-therapy
#2
Theodora Tsirouki, Alexandra Bargiota, Stelios Tigas, Agathi Vasileiou, Eftichia Kapsalaki, Zoe Giotaki, Ioannis Asproudis, Agathokles Tsatsoulis, Georgios Koukoulis, Evangelia E Tsironi
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of an individualized steroid regimen in patients with moderate-to-severe Graves' orbitopathy (GO) by monitoring clinical and imaging parameters. METHODS: In total, 47 patients with active, moderate-to-severe GO were enrolled in this study. All the patients received the proposed treatment regimen by European Group on GO of 4.5 g of intravenous (IV) methylprednisolone for 12 weeks. At the end of the IV treatment, patients with persistent active GO (Group 1) who were assessed by clinical examination and orbital imaging with short tau inversion recovery-sequence magnetic resonance imaging (STIR MRI) received additional treatment with oral prednisolone, and those with inactive GO (Group 2) received no further treatment...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27871109/-graves-orbitopathy
#3
A Eckstein, J Esser, S Mattheis, U Berchner-Pfannschmidt
No abstract text is available yet for this article.
November 21, 2016: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/27863789/comparative-analysis-of-radioactive-iodine-versus-thyroidectomy-for-definitive-treatment-of-graves-disease
#4
Vincent T Wu, Allison W Lorenzen, Anna C Beck, Vincent J Reid, Sonia L Sugg, James R Howe, Janet H Pollard, Geeta Lal, Ronald J Weigel
BACKGROUND: Management of Graves disease includes antithyroid drugs, (131)I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease. METHODS: This was a retrospective review of patients undergoing (131)I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases. RESULTS: (131)I therapy patients were older (39...
November 15, 2016: Surgery
https://www.readbyqxmd.com/read/27843806/a-2016-italian-survey-about-the-clinical-use-of-selenium-in-thyroid-disease
#5
Roberto Negro, Roberto Attanasio, Franco Grimaldi, Claudio Marcocci, Rinaldo Guglielmi, Enrico Papini
BACKGROUND: Selenium (Se) is a trace element that plays key roles in thyroid physiology. Se deficiency is associated with increased risk of thyroid disease. Some evidence suggests that Se supplementation may be beneficial in autoimmune thyroid disease (either hypo- or hyperthyroidism). OBJECTIVES: We sought to examine the use of Se in daily clinical practice among Italian endocrinologists. METHODS: Members of the Associazione Medici Endocrinologi (AME) were invited to participate in a web-based survey investigating the use of Se in different clinical conditions...
September 2016: European Thyroid Journal
https://www.readbyqxmd.com/read/27828690/immunoglobulin-g4-related-thyroid-disorders-diagnostic-challenges-and-clinical-outcomes
#6
Deep Dutta, Arvind Ahuja, Chitra Selvan
Ig-G4 related disease (IgG4RD) is a heterogeneous disorder with multi-organ involvement recognised as a separate entity at the start of this century only. It is currently one of the hottest areas of clinical and translational research across specialties. Thyroid involvement in IgG4RD is rare, believed to occur in less than 4% of cases, may be isolated or may be associated with other organ involvement. As of today Riedel's thyroiditis, fibrosing variant of Hashimoto's thyroiditis, and few patients of Graves' orbitopathy represent the types of IgG4-related thyroid disease (IgG4RTD)...
2016: Endokrynologia Polska
https://www.readbyqxmd.com/read/27824294/anti-oxidant-actions-of-selenium-in-orbital-fibroblasts-a-basis-for-the-effects-of-selenium-in-graves-orbitopathy
#7
Giovanna Rotondo Dottore, Marenza Leo, Giamberto Casini, Francesco Latrofa, Luca Cestari, Stefano Sellari-Franceschini, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marino
Background A recent clinical trial has shown a beneficial effect of the antioxidant agent selenium in Graves' orbitopathy (GO). In order to shed light on the cellular mechanisms on which selenium may act, here we investigated its effects in cultured orbital fibroblasts. Methods Primary cultures of orbital fibroblasts from 6 GO patients and 6 control subjects were established. Cells were treated with H2O2 to induce oxidative stress, after pre-incubation with selenium-(Methyl)selenocysteine (SeMCys). The following assays were performed: glutathione disulfide (GSSG), as a measure of oxidative stress, glutathione peroxidase (GPX) activity, cell proliferation, hyaluronic acid (HA) and pro-inflammatory cytokines...
November 8, 2016: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/27780830/can-we-predict-relapse-in-graves-disease-results-from-a-systematic-review-and-meta-analysis
#8
Tristan Struja, Hannah Fehlberg, Alexander Kutz, Larissa Guebelin, Christian Degen, Beat Mueller, Philipp Schuetz
BACKGROUND: Identification of pretreatment risk factors predicting relapse in patients with hyperthyroidism of Graves' disease after stopping anti-thyroid drugs (ATD) is decisive to guide therapeutic options. PURPOSE: We performed a systematic search and meta-analysis to study predictors for relapse after stopping ATD in patients with Graves' disease. METHODS: Based on a pre-specified protocol, we searched PubMed, EMBASE and Cochrane in July 2015 for case-control, controlled and randomized-controlled trials reporting risk factors for relapse after stopping ATD...
January 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27760790/management-of-endocrine-disease-rituximab-therapy-for-graves-orbitopathy-lessons-from-randomized-control-trials
#9
REVIEW
Marius N Stan, Mario Salvi
Rituximab (RTX) use in open-label series has been associated with very encouraging responses in patients with active and moderate-to-severe Graves' orbitopathy (GO). Recently, randomized controlled trials of RTX have been performed in such patients to answer the question of clinical efficacy and the safety profile of this agent. That data, reported separately, focused on Clinical Activity Score (CAS) and indicated in one trial a strong benefit of RTX in comparison with IV glucocorticoids, whereas the other trial noted the absence of a benefit by comparison with placebo...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27734978/surgical-complications-in-orbital-decompression-for-graves-orbitopathy
#10
S Sellari-Franceschini, I Dallan, A Bajraktari, G Fiacchini, M Nardi, R Rocchi, C Marcocci, M Marinò, A P Casani
The objective of this study is to analyse the complications of orbital decompression in Graves' orbitopathy. The clinical records of 946 patients who had been operated on with orbital decompression for Graves' orbitopathy were reviewed and the intra- and post-operative complications with minimum follow-up of six months were analysed. An extensive review of the literature was carried out to compare results. In the case-series reported here the most frequent complications were: wasting of the temporal region (100%) in patients operated on using a coronal approach; permanent hypoesthesia of V2 (13%) and V1 (8%) in patients operated on with an upper eyelid incision...
August 2016: Acta Otorhinolaryngologica Italica
https://www.readbyqxmd.com/read/27734693/-endocrine-orbitopathy-the-topic-still-alive
#11
Zdeněk Fryšák, David Karásek, Milan Halenka
Endocrine orbitopathy (EO) must be understood mainly as a result of oxidative stress. The pathological process finally affects both the appearance and vision of the patient. In the case of inappropriate or late treatment or lack of patient cooperation, it significantly influences the quality of life of those affected. In spite of the sophisticated dia-gnostic algorithms, in some cases it is difficult to confirm the diagnosis of EO. The range of laboratory methods, the essential part of the diagnostic process, has only recently been extended by the possibility of quantification of specific, stimulating immunoglobulins (TSI)...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27732097/variables-affecting-the-long-term-outcome-of-graves-orbitopathy-following-high-dose-intravenous-glucocorticoid-pulse-therapy-in-patients-not-treated-with-orbital-radiotherapy
#12
Marenza Leo, Teresa Mautone, Ilaria Ionni, Maria Antonietta Profilo, Elena Sabini, Francesca Menconi, Barbara Mazzi, Roberto Rocchi, Francesco Latrofa, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marinò
OBJECTIVE: Intravenous (iv) glucocorticoids (GC) (ivGC) are used for active Graves orbitopathy (GO), but factors affecting GO outcome are poorly understood. We performed a retrospective study to investigate the variables affecting GO after ivGC. METHODS: We evaluated 83 consecutive GO patients treated with ivGC but not orbital radiotherapy (ORT) and re-examined them after a median of 47 months. The endpoints were the relationships between GO outcome or additional treatments with age, sex, smoking habits, thyroid volume, thyroid treatment, time since thyroid treatment, antithyroid-stimulating hormone receptor antibodies (TRAb), GO duration, GO features, and follow-up time...
October 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27715404/severe-pediatric-graves-orbitopathy-in-adolescents-of-african-origin
#13
Andrea Papp, Clemence Vasserot-Merle, Guido Dorner, Dion Paridaens
This article reports on two cases of severe pediatric Graves orbitopathy (GO) in two adolescents of African origin. Two black male adolescents presented with highly active GO and signs of beginning compressive optic neuropathy. Neither of them were smokers nor had a family history of GO. Besides urgent referral to pediatric endocrinologists, intravenous methylprednisolon pulse therapy was initiated. In spite of the fluctuating thyroid hormone levels in the initial phase of antithyroid therapy, intravenous steroid administration stopped the progression of malignant GO rapidly in both of our patients without any considerable side effects...
August 12, 2016: Orbit
https://www.readbyqxmd.com/read/27709471/natural-history-of-graves-orbitopathy-after-treatment
#14
Francesca Menconi, Marenza Leo, Elena Sabini, Teresa Mautone, Marco Nardi, Aldo Sainato, Stefano Sellari-Franceschini, Paolo Vitti, Claudio Marcocci, Michele Marinò
Intravenous glucocorticoids are used for Graves' orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery). However, the relation between associated/additional treatments and other variables with Graves' orbitopathy outcome following intravenous glucocorticoids is not clear. Thus, the present study was conducted to investigate retrospectively the impact of associated/additional treatments and other variables on Graves' orbitopathy outcome after intravenous glucocorticoids...
October 5, 2016: Endocrine
https://www.readbyqxmd.com/read/27682712/an-update-on-thyroid-associated-ophthalmopathy-in-children-and-adolescents
#15
Justyna Szczapa-Jagustyn, Anna Gotz-Więckowska, Jarosław Kocięcki
BACKGROUND: Risk of developing thyroid-associated ophthalmopathy (TAO) in children and adolescents is similar or may be even slightly higher than in adults. The aim of this article is to review and summarize current knowledge regarding diagnostic and therapeutic measures in pediatric TAO. CONTENT: MEDLINE and EMBASE papers were searched using the terms 'pediatric Graves' ophthalmopathy' 'pediatric Graves' orbitopathy', 'thyroid-associated ophthalmopathy in childhood and adolescence' from the year 1970 to December 2015...
October 1, 2016: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/27664101/natural-course-of-mild-graves-orbitopathy-is-it-a-chronic-remitting-or-a-transient-disease
#16
P Anagnostis, K Boboridis, F Adamidou, M Kita
BACKGROUND/AIMS: The natural course of Graves' orbitopathy (GO) has been poorly documented. The aim of this review is to provide current knowledge regarding the natural course of mild GO, trying to address the issue of whether and to what extent it constitutes a chronic remitting or transient disease. METHODS: We systematically searched PubMed for English language publications until August 2016 under the following terms: "Graves' orbitopathy" OR "Graves' ophthalmopathy" OR "thyroid eye disease" AND "natural course" OR "natural history"...
September 23, 2016: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/27638540/cd28-ctla-4-icos-haplotypes-confers-susceptibility-to-graves-disease-and-modulates-clinical-phenotype-of-disease
#17
Edyta Pawlak-Adamska, Irena Frydecka, Marek Bolanowski, Anna Tomkiewicz, Anna Jonkisz, Lidia Karabon, Anna Partyka, Oskar Nowak, Marek Szalinski, Jacek Daroszewski
Graves' disease, an autoimmune disease with heterogeneous symptoms including Graves' orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers.Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves' disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves' disease patients...
September 16, 2016: Endocrine
https://www.readbyqxmd.com/read/27628269/is-modified-clinical-activity-score-an-accurate-indicator-of-diplopia-progression-in-graves-orbitopathy-patients
#18
Ji Won Kim, Young Jun Woo, Jin Sook Yoon
The aim of this study is to describe characteristics of Graves' orbitopathy (GO) patients with progressive diplopia and to consider whether modified clinical activity score (CAS) is a useful indicator for prediction of diplopia progression. Medical records and images of GO patients with progressive diplopia were retrospectively reviewed. Clinical parameters (e.g., modified CAS, modified NOSPECS score, exophthalmometry results, score of diplopia, and prevalence of optic neuropathy) were evaluated. Thyroid stimulating hormone receptor autoantibody (TRAb) values were determined...
September 13, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27609530/medial-and-mediolateral-orbital-decompression-in-intractable-graves-orbitopathy
#19
Ira Seibel, Veit Maria Hofmann, Hasibe Sönmez, Shideh Schönfeld, Masen Dirk Jumah, Minoo Lenarz, Annekatrin Coordes
OBJECTIVE: Graves' Orbitopathy (GO) has well established treatment guidelines; however, its management is still controversial. The aim was to evaluate the results of medial and mediolateral orbital decompression (OD) in intractable GO. METHODS: Retrospective chart review of all patients with advanced stages of GO, who underwent medial (1-wall) or mediolateral (2-wall) OD between May 2012 and November 2014 in our institution. Ophthalmologic examinations included visual acuity, Hertel exophthalmometry (proptosis), intraocular pressure (IOP), visual field (30:2) and diplopia...
September 5, 2016: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/27552248/pathogenic-phenotype-of-adipogenesis-and-hyaluronan-in-orbital-fibroblasts-from-female-graves-orbitopathy-mouse-model
#20
Gina-Eva Görtz, Sajad Moshkelgosha, Christoph Jesenek, Bärbel Edelmann, Mareike Horstmann, J Paul Banga, Anja Eckstein, Utta Berchner-Pfannschmidt
A mouse model of Graves' orbitopathy (GO) induced by genetic immunization of human TSH receptor (TSHR) A-subunit encoding plasmid has recently been established. The orbital pathology was characterized by adipogenesis, myopathy and fibrosis. Human orbital fibroblasts (OFs) express TSHR and IGF-1 receptor (IGF-1R) and are considered to be pathogenic in GO. We established conditions for growing ex vivo cultures of mouse OFs (mOFs) from orbital tissue of animals undergoing GO and controls. Early passage mOFs showed characteristic fibroblast morphology and expressed mesenchymal stem cell markers including a strong expression of CD90...
October 2016: Endocrinology
keyword
keyword
33773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"